The Federal Trade Commission is accusing several drugmakers of violating antitrust laws with agreements that delayed availability of cheaper generic versions of two pain treatments. It's the first so-called "pay for delay" case brought by the commission in which a drug's original maker agreed not to sell an "authorized generic" version until well after a generic drugmaker launched its product.